Aptose Biosciences Inc (FRA:LTI)
€ 0.36 0.016 (4.65%) Market Cap: 6.97 Mil Enterprise Value: 65,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Aptose Biosciences Inc To Hold Clinical Update Call Transcript

Oct 30, 2023 / 12:30PM GMT
Release Date Price: €3 (+14.50%)
Operator

Good afternoon. I would like to welcome everyone to the Aptose Biosciences' clinical update and data review in conjunction with the European School of Hematology, ESH 6th International Conference. (Operator Instructions) After the speakers' remarks, there will be a question-and-answer session.

Joining me on today's call are Dr. William Rice, Chairman and CEO; Dr. Rafael Bejar, Senior Vice President, Chief Medical Officer; and our special guest and key opinion leader, Dr. Naval Daver from the MD Anderson Cancer Center.

I will now turn the call over to Dr. Rice, Chairman and CEO of Aptose Biosciences. Please go ahead.

William Rice
Aptose Biosciences Inc. - Chairman, President & CEO

Thank you. Good morning, all. Today, we'll come to you from the European School of Haematology Conference being held in Estoril, Portugal. It's my pleasure to welcome you to our clinical update and KOL data review for Aptose's lead agent Tuspetinib that's being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia or AML. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot